Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    24907225 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
Condition: Hepatitis C
Interventions: Drug: Placebo;   Drug: TMC435;   Drug: Peginterferon alpha-2a (PegIFN alpha-2a);   Drug: Ribavirin (RBV)

Indicates status has not been verified in more than two years